Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218887 · ClinicalTrials.gov registry record · Phase 1
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
A Phase 1 study of BAG3 Mutation Associated Dilated Cardiomyopathy, sponsored by Alexion Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 7
- Study locations
NCT07218887 is a Phase 1 study of BAG3 Mutation Associated Dilated Cardiomyopathy that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 6 participants. The trial reports 7 study locations across 6 states.
The verdict
NCT07218887, a Phase 1 study of BAG3 Mutation Associated Dilated Cardiomyopathy, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 7
- Study locations
Study Summary
This Phase 1/2 study is an open-label, dose finding and dose expansion study investigating the safety, tolerability, and efficacy of a single IV infusion of ALXN2350 in adult participants with BAG3 associated DCM.
Conditions Studied
Interventions
- DRUG ALXN2350
Study Locations (7)
Other
- Research Site - Barcelona
- Research Site - Majadahonda
Alabama
- Research Site - Birmingham
Massachusetts
- Research Site - Boston
Ohio
- Research Site - Cincinnati
Oregon
- Research Site - Portland
Texas
- Research Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2025-10-24 |
| Est. Completion | 2032-01-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07218887
The ClinicalTrials.gov registry entry for NCT07218887 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with BAG3 Mutation Associated Dilated Cardiomyopathy appearing as the primary indexed condition, and to 1 intervention - of which ALXN2350 is the first listed.
NCT07218887 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Other, Alabama, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07218887 about?
NCT07218887 is a clinical study titled "ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy". This Phase 1/2 study is an open-label, dose finding and dose expansion study investigating the safety, tolerability, and efficacy of a single IV infusion of ALXN2350 in adult participants with BAG3 associated DCM.
What is the current status of trial NCT07218887?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2025-10-24. Estimated completion is 2032-01-27.
What conditions does trial NCT07218887 study?
This clinical trial studies the following conditions: BAG3 Mutation Associated Dilated Cardiomyopathy.
What interventions are being tested in trial NCT07218887?
The interventions under investigation include: ALXN2350 (DRUG).
Who is sponsoring clinical trial NCT07218887?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07218887 being conducted?
This trial has 7 study locations across Alabama, Massachusetts, Ohio, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.